Loading
FORT MYERS - NeoGenomics has created new cancer tests that can help physicians monitor tumors without the need for tissue biopsies.
The liquid biopsy tests analyze blood plasma surrounding the tumors to monitor progression of certain types of cancers. NeoGenomics recently announced it has added two new tests that will help physicians monitor patients with certain kinds of lymphoma and leukemia.
Early detection of potential resistance may alert the treating physician to develop a new strategy for therapy or for a combination of therapies that may overcome resistance, the company says.
“Our goal for these two new tests is to help physicians make the proper change in therapy and replace expensive drugs that are not working with drugs that have the potential to work,” says Maher Albitar, the company's chief medical officer and director of research and development, in a statement.
“The added medical value that liquid biopsies provide is now well recognized,” says Douglas VanOort, NeoGenomics' chairman and CEO, in a statement. “These new tests bring our menu of innovative liquid biopsy offerings to a total of 15 tests and demonstrate our commitment to being a leader in personalized medicine testing in order to improve patient care.”
NeoGenomics is headquartered in Fort Myers. The company operates labs in Tampa, Nashville, Irvine, Calif., and Sacramento.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
